
CLAIMS

1. An antisense oligomer of Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, wherein:

each Nu is a nucleobase which taken together form a targeting sequence;

Z is an integer from 20 to 26;

T is a moiety selected from:



wherein R^3 is C_1-C_6 alkyl; and

R^2 is selected from H, acetyl, trityl, and 4-methoxytrityl,

wherein the targeting sequence is complementary to an exon 45 target region selected from the group consisting of H45A(-06+20), H45A(-03+19), H45A(-09+16), H45A(-09+19), and H45A(-12+16).

2. The antisense oligomer of claim 1, wherein the targeting sequence is selected from:


a) SEQ ID NO: 1 (5'-CCAATGCCATCCTGGAGTTCCTGTAA-3'), wherein Z is 24;

b) SEQ ID NO: 2 (5'-CAATGCCATCCTGGAGTTCCTG-3'), wherein Z is 20;

c) SEQ ID NO: 3 (5'-TGCCATCCTGGAGTTCCTGTAAGAT-3'), wherein Z is 23;

d) SEQ ID NO: 4 (5'-CAATGCCATCCTGGAGTTCCTGTAAGAT-3'), wherein Z is 26; and

e) SEQ ID NO: 5 (5'-TGCCATCCTGGAGTTCCTGTAAGATACC-3'), wherein Z is 26.

3. The antisense oligomer of claim 1 or 2, wherein T is 

.

4. The antisense oligomer of any one of claims 1-3, wherein R^2 is H.

5. The antisense oligomer of any one of claims 1-4, wherein Z is 24.

6. The antisense oligomer of any one of claims 1-4, wherein Z is 20.

7. The antisense oligomer of any one of claims 1-4, wherein Z is 23.

8. The antisense oligomer of any one of claims 1-4, wherein Z is 26.

9. The antisense oligomer of any one of claims 1-4, wherein the targeting sequence is SEQ ID NO: 1 (5'-CCAATGCCATCCTGGAGTTCCTGTAA-3') and Z is 24.


10. The antisense oligomer of any one of claims 1-4, wherein the targeting sequence is SEQ ID NO: 2 (5'-CAATGCCATCCTGGAGTTCCTG-3') and Z is 20.

11. The antisense oligomer of any one of claims 1-4, wherein the targeting sequence is SEQ ID NO: 3 (5'-TGCCATCCTGGAGTTCCTGTAAGAT-3') and Z is 23.

12. The antisense oligomer of any one of claims 1-4, wherein the targeting sequence is SEQ ID NO: 4 (5'-CAATGCCATCCTGGAGTTCCTGTAAGAT-3') and Z is 26.

13. The antisense oligomer of any one of claims 1-4, wherein the targeting sequence is SEQ ID NO: 5 (5'-TGCCATCCTGGAGTTCCTGTAAGATACC-3') and Z is 26.

14. The antisense oligomer of claim 1, selected from the group consisting of:




Compound 1

wherein each Nu from 1 to 26 and 5' to 3' is:

Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu
1	C	6	G	11	C	16	A	21	C	26	A

2	C	7	C	12	C	17	G	22	T		
3	A	8	C	13	T	18	T	23	G		
4	A	9	A	14	G	19	T	24	T		
5	T	10	T	15	G	20	C	25	A		

and




Compound 2

wherein each Nu from 1 to 22 and 5' to 3' is:

Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu
1	C	6	C	11	C	16	G	21	T
2	A	7	C	12	T	17	T	22	G
3	A	8	A	13	G	18	T		
4	T	9	T	14	G	19	C		
5	G	10	C	15	A	20	C		

and




Compound 3

wherein each Nu from 1 to 25 and 5' to 3' is:

Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu
1	T	6	T	11	G	16	C	21	A
2	G	7	C	12	A	17	C	22	A
3	C	8	C	13	G	18	T	23	G
4	C	9	T	14	T	19	G	24	A
5	A	10	G	15	T	20	T	25	T

and




Compound 4

wherein each Nu from 1 to 28 and 5' to 3' is:

Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu
1	C	6	C	11	C	16	G	21	T	26	G
2	A	7	C	12	T	17	T	22	G	27	A
3	A	8	A	13	G	18	T	23	T	28	T
4	T	9	T	14	G	19	C	24	A		
5	G	10	C	15	A	20	C	25	A		

and







Compound 5


wherein each Nu from 1 to 28 and 5' to 3' is:

Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu
1	T	6	T	11	G	16	C	21	A	26	A
2	G	7	C	12	A	17	C	22	A	27	C
3	C	8	C	13	G	18	T	23	G	28	C
4	C	9	T	14	T	19	G	24	A		
5	A	10	G	15	T	20	T	25	T		

.

wherein for each of Compounds 1 to 5, A is , C is , G is , and T is .

15. The antisense oligomer of claim 1, selected from:



Compound 2

wherein each Nu from 1 to 22 and 5' to 3' is:

Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu	Position No. 5' to 3'	Nu
1	C	6	C	11	C	16	G	21	T
2	A	7	C	12	T	17	T	22	G
3	A	8	A	13	G	18	T		
4	T	9	T	14	G	19	C		

5	G	10	C	15	A	20	C		

16. A pharmaceutical composition comprising the antisense oligomer of any one of claims 1-15 and a pharmaceutically acceptable carrier.

17. The antisense oligomer of any one of claims 1-15 for use in the treatment of Duchenne muscular dystrophy (DMD).

18. Use of the antisense oligomer of any one of claims 1-15 in the manufacture of a medicament for the treatment of Duchenne muscular dystrophy (DMD) or production of dystrophin in a subject in need thereof, wherein the subject has a mutation of the dystrophin gene that is amenable to exon 45 skipping.